Abstract
Background
HCV is associated with several extra hepatic diseases including thyroid dysfunction. This study aims at evaluating prevalence of thyroid dysfunction and its possible predictors in a large cohort of HCV GT4-infected patients, and the role of thyroid dysfunction as a predictor of response in the setting of direct acting antivirals (DAAs).
Methods
Patients registered on the web-based registry system to receive therapy for chronic HCV in Beheira governorate viral hepatitis specialized treatment center affiliated to the National committee for control of viral hepatitis (NCCVH), Ministry of health, Egypt in the period from January 2015 to October 2016. Their data were exported and analyzed for the prevalence of thyroid dysfunction and its associated variables.
Results
Out of 13,402 patients, 2833 (21.1%) had elevated TSH level > 4.5 mIU/l (hypothyroidism). Female gender (62.7%), older age, higher FIB4, AST, and BMI and lower albumin were significantly associated with elevated TSH level on univariate analysis, while liver stiffness measured by fibroscan was not significantly associated. On the other hand, 466 patients (3.5%) showed low TSH level < 0.4 mIU/l (hyperthyroidism). Older age (median 52 years) and male gender (51.5%) were the only significantly associated variables. No association was found between SVR and baseline TSH level. Follow-up of 236 patients after SVR revealed improvement in TSH level in 80% of them.
Conclusion
Hypothyroidism is prevalent in patients with chronic HCV GT4, and is influenced by patient gender and age. Pretreatment TSH does not affect SVR after DAAs. Despite limited data SVR achievement after DAAs improves thyroid dysfunction.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Fallahi P, Ferrari SM, Ruffilli I, Elia G, Giuggioli D, Colaci M. Incidence of thyroid disorders in mixed cryoglobulinemia: Results from a longitudinal follow-up. Autoimmun Rev 2016 [In press].
Tomer Y, Villanueva R. Hepatitis C and thyroid autoimmunity: is there a link? Am J Med 2004;117:60–61.
Tomer Y. Hepatitis C and interferon induced thyroiditis. J Autoimmun 2010;34:322–3226.
Ferri C, Ramos-Casals M, Zignego AL, On behalf of the ISG-EHCV coauthors, et al. International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. Autoimmun Rev 2016. https://doi.org/10.1016/j.autrev.2016.09.006 (Article in press).
Indolfi G, Stagi S, Bartolini E, et al. Thyroid function and antithyroid autoantibodies in untreated children with vertically acquired chronic hepatitis C virus infection. Clin Endocrinol 2008;68:117–121.
Antonelli A, Ferri C, Fallahi P. Hepatitis C: thyroid dysfunction in patients with hepatitis C on IFN-alpha therapy. Nat Rev Gastroenterol Hepatol 2009;6:633–635.
Prummel MF, Laurberg P. Interferon-α and autoimmune thyroid disease. Thyroid 2003;13:547–551.
Rugge B, Balshem H, Sehgal R, Relevo R, Gorman P, Helfand M. Screening and treatment of subclinical hypothyroidism or hyperthyroidism. Comparative Effectiveness Review No. 24. Rockville, MD: Agency for Healthcare Research and Quality; 2011.
LeFevre ML. Screening for thyroid dysfunction: U.S. preventive services task force recommendation statement. Ann Intern Med 2015;162(9):641–650.
Vanderpump MP, Tunbridge WM. The epidemiology of thyroid diseases. In: Braverman LE, Utiger RD, editors. The thyroid: a fundamental and clinical text. 8th ed. Philadelphia: Lippincott Williams and Wilkins; 2000. p. 467–473.
Antonelli A, Ferri C, Pampana A, et al. Thyroid disorders in chronic hepatitis C. Am J Med 2004;117(1):10–13.
Andrade LJ, Atta AM, Atta ML, Mangabeira CN, Parana R. Thyroid disorders in patients with chronic hepatitis C using interferon-alpha and ribavirin therapy. Braz J Infect Dis 2011;15(4):377–381.
Progress for Children. A report card on nutrition, Number 4, May 2006. New York: UNICEF; 2006.
Marazuela M, Garcia-Buey L, Gonzalez-Fernandez B, et al. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy. Clin Endocrinol (Oxf) 1996;44:635–642.
Pavan MH, Pavin EJ, Goncales FL, Wittmann DE. Virus C genotype predisposes to primary hypothyroidism during interferon-α treatment for chronic hepatitis C. Braz J Infect Dis 2011;15(5):449–456.
Huang MJ, Liaw YF. Clinical associations between thyroid and liver diseases. J Gastroenterol Hepatol 1995;10:344–350.
Rodríguez-Torres M, Ríos-Bedoya CF, Ortiz-Lasanta G, Marxuach-Cuétara AM, Jiménez-Rivera J. Thyroid dysfunction (TD) among chronic hepatitis C patients with mild and severe hepatic fibrosis. Ann Hepatol 2008;7(1):72–77.
El-Atrebi KA, El-Bassyouni HT, Zaki NA. Thyroid dysfunction as predictor of sustained virological response (SVR) During HCV treatment with PEGylated interferon and ribavirin. Int J Pharm Clin Res 2016;8(6):628–631.
Gill K, Ghazinian H, Manch R, Gish R. Hepatitis C virus as a systemic disease: reaching beyond the liver. Hepatol Int 2016;10:415–423.
Acknowledgements
No funding source to be acknowledged.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that there is no conflict of interest.
Research involving human participants
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Eletreby, R., Said, M., Abdellatif, Z. et al. High prevalence of HCV (GT4)-related TSH abnormality among 13402 Egyptian patients treated with direct acting antiviral therapy. Hepatol Int 12, 143–148 (2018). https://doi.org/10.1007/s12072-018-9845-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12072-018-9845-2